Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CoTherix has entered into a collaborative R&D agreement with UK-based Quadrant Drug Delivery Limited to develop an extended-release formulation of the pulmonary arterial hypertension treatment, Ventavis inhalation solution.
Subscribe to our email newsletter
The goal of this initiative is to reduce the frequency and duration of dosing. Ventavis (iloprost) is marketed by CoTherix in the US for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization Group I) in patients with NYHA Class III or IV symptoms.
“Our goal is to provide greater patient convenience by reducing the number of doses required per day and enabling dose delivery in a single breath using a pocket-sized device,” said Dr Curtis Ruegg, senior vice president of technical operations at CoTherix. “Ventavis is extremely potent and stable, making it an ideal candidate for extended-release reformulation.”
“We are delighted to have this opportunity to apply our dry powder formulation technologies developed over the last 10 years to help create an extended-release formulation of Ventavis,” added Raj Uppal, CEO of Quadrant. “We are confident we can assist CoTherix in improving the Ventavis formulation.”